Clinical trials: Dementia Alzheimers
Alzheimer Disease
A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's
The purpose of this study is to evaluate safety and target engagement of XPro1595 in Alzheimer's patients with biomarkers of inflammation.
- Trial name
- NCT03943264
- Testing
- XPro1595
- Where
- 5 sites in Australia
- Volunteers
- 20 people
- Sponsor
- Inmune Bio, Inc.
Subjective Cognitive Decline, Preclinical Alzheimer's Disease
Prediction of Cognitive Decline by Neuroimaging Techniques and the Application in Diagnosis and Treatment of Preclinical AD
This study is affiliated to Sino Longitudinal Study on Cognitive Decline, SILCODE. To establish models of normal and pathological cognitive aging.To collect the longitudinal data of SCD population, to study the dynamic changes of…
- Trial name
- NCT03370744
- Testing
- Neuropsychological scale
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- XuanwuH 2
Alzheimer's Disease
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
The purpose of the study is to evaluate the safety and tolerability of ascending oral doses of CHF 5074 after prolonged administration to patients with mild cognitive impairment.
- Trial name
- CT04 POLEP (NCT01602393)
- Testing
- CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
- Where
- 5 sites in United States, Italy
- Volunteers
- 51 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Alzheimer s Disease, Alzheimer Dementia
Fisetin in Mild Alzheimer's Disease
This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.
- Conditions
- Alzheimer s Disease, Alzheimer Dementia, Alzheimer Dementia (AD), Alzheimer Disease
- Trial name
- FIS-AD (NCT07279714)
- Testing
- Fisetin
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Sunnybrook Health Sciences Centre
Cognition Disorders
Brain Imaging and Mental Disorders of Aging Intervention
The goal of this project is to determine if a cholinesterase inhibitor is more effective than placebo in delaying cognitive and brain functional decline in people at risk for Alzheimer's disease.
- Trial name
- NCT00267163
- Testing
- donepezil
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- National Institute on Aging (NIA)
Alzheimer Disease, Frail Elderly Syndrome
Comparison of Kinesiophobia, Balance, Falling and Walking Speeds of Elderly's With Physical Frailty With Alzheimer's
In this study, Kinesiophobia, Balance, Falling, Walking Speeds of Elderly People with Cognitive Frailty with Alzheimer's Dementia, Elderly with Physical Frailty and Healthy Elderly Individuals will be compared.
- Trial name
- NCT05761665
- Testing
- Evaluation
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Kırıkkale University
Alzheimer Disease
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory…
- Trial name
- NCT05999084
- Testing
- Anti-amyloid Monoclonal Antibodies (mAbs), Standard of Care
- Where
- 8 sites in United States
- Volunteers
- 735 people
- Sponsor
- Emory University
Alzheimer Disease
Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease
This substudy will evaluate the effect of crenezumab on the longitudinal tau burden in a subgroup of preclinical Presenilin1 (PSEN1) E280A mutation carriers and non-carriers, who were enrolled in study NCT01998841 (GN28352).
- Trial name
- NCT03977584
- Testing
- Crenezumab, [^18F]GTP1
- Where
- Colombia
- Volunteers
- 114 people
- Sponsor
- Hoffmann-La Roche
Healthy, Adult
Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects
Primary: To evaluate the pharmacologic effect of single doses of SAM-531 on sleep EEG in healthy subjects.
- Trial name
- NCT00519298
- Testing
- SAM-531, Donepezil
- Where
- France
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Primary Care, Alzheimer Disease
Designing a Tailored Primary Care Intervention to Manage the Burden of Caring for Patients Living with Alzheimer's Disease (or a Related Dementia)
The design of the intervention is an ongoing process which will consist of two phases: a determination of the intervention using the Delphi-modified consensus method and an assessment of its acceptability, as described in the…
- Trial name
- ISAMA-PP (NCT06852326)
- Where
- 3 sites in France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Mild Cognitive Impairment, Mild to Moderate Dementia
Adaptive Cognitive Training in Healthy Older Adults
Cognitive training has emerged as a promising method to maintain, enhance, and rehabilitate cognitive function in older adults and individuals with dementia.
- Conditions
- Mild Cognitive Impairment, Mild to Moderate Dementia, Alzheimer's Disease
- Trial name
- NCT02205710
- Testing
- Computerized cognitive training, Computerized games
- Where
- Canada
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Bruyère Health Research Institute.
Epilepsy, Alzheimer Disease
Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects
Study NPT 2042 CL 101 is a first in human (FIH) study to evaluate the safety and pharmacokinetics (PK) of single and repeated ascending doses of NPT 2042 in healthy adult male and female subjects.
- Conditions
- Epilepsy, Alzheimer Disease, Epilepsy Intractable
- Trial name
- NCT05503511
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- NeuroPro Therapeutics, Inc.
Dementia, Dementia Alzheimers
A Spanish-language Caregiver-Enabled Care Program
The purpose of the study is to develop and test the feasibility of a nonmedical digital health intervention, the Spanish-language Caregiver-Enabled Care Program (CECP), with Spanish-speaking caregivers of persons with dementia…
- Conditions
- Dementia, Dementia Alzheimers, Alzheimer Disease, Caregiver
- Trial name
- CECP (NCT06631144)
- Testing
- Spanish-language Caregiver-Enabled Care Program (CECP)
- Where
- United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Ceresti Health, Inc.
Caregivers, Alzheimer's Disease
Meditation or Education for Alzheimer Caregivers
The goal is to determine how 6-week stress reduction techniques may decrease stress in primary caregivers of people with Alzheimer's disease. The 3 intervention programs are meditation, education, and respite care.
- Trial name
- NCT00558402
- Testing
- Meditation, Education, Respite only
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Oregon Health and Science University
Alzheimer Disease
Learning Amyloid and Tau Results
This is a prospective, single-cohort, single-center, observational study to assess if learning one's Alzheimer's disease biomarker test result impacts longitudinal psychosocial, behavioral, and neuropsychological outcomes, and to…
- Trial name
- NCT07222930
- Testing
- Disclose amyloid, tau results, Follow-up Assessments
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Genetic Risk for Alzheimer's Disease
Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease
This study examines the sensitivity of functional MRI to detect brain changes caused by donepezil HCL (a cholinesterase inhibitor) in healthy older adults at genetic risk for Alzheimer's Disease.
- Trial name
- NCT02087865
- Testing
- donepezil HCL
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Alzheimer's Disease, Hypogonadism
Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone
Treatment with testosterone can improve performance on tests of spatial ability in men with low testosterone levels and Alzheimer's disease.
- Trial name
- NCT00392912
- Testing
- AndroGel (Solvay Pharmaceuticals)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Dementia, Dementia, Vascular
Enhancing Care Coordination: Hospital to Home for Cognitively Impaired Older Adults and Their Caregivers
Aim 1. To compare across three hospital sites the effects on health and cost outcomes observed by the following three interventions, each designed to enhance adaptation and improve outcomes of hospitalized cognitively impaired…
- Conditions
- Dementia, Dementia, Vascular, Alzheimer Disease, Delirium, Dementia, Amnestic, Cognitive Disorders
- Trial name
- NCT00294307
- Testing
- Augmented Standard Care (ASC), Resource Nurse Care (RNC), Advanced Practice Nurse Care (APNC)
- Where
- 3 sites in United States
- Volunteers
- 814 people
- Sponsor
- University of Pennsylvania
Alzheimer Disease
Study on Novel Peripheral Blood Diagnostic Biomarkers for MCI Due to Alzheimer's Disease
The prevalence of Mild Cognitive Impairment (MCI) is about 15%-17%. 10%-15% of MCI progresses to Alzheimer's disease (AD) every year. The annual incidence of MCI in the normal elderly is about 1%.
- Trial name
- Precision1000 (NCT04509271)
- Testing
- MicRNAs battery kits
- Where
- China
- Volunteers
- 1,300 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Alzheimer's Disease, Huntington's Disease
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
This study is to compare the pharmacokinetics of Dimebon in subjects with severe renal impairment to subjects with normal renal function after oral administration of a single oral 20-mg dose of Dimebon.
- Trial name
- NCT00824590
- Testing
- Dimebon
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.